William G Dixon
University of Manchester
220 Papers
579 Citations
William G Dixon is an academic researcher from University of Manchester. The author has contributed to research in topics: Medicine & Rheumatoid arthritis. The author has an hindex of 45, co-authored 186 publications. Previous affiliations of William G Dixon include Central Manchester University Hospitals NHS Foundation Trust & Arthritis Research UK.
Chat about Author
Papers
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis : a European registries collaborative project
Louise K. Mercer,Anne C. Regierer,Xavier Mariette,William G Dixon,Eva Baecklund,Karin Hellgren,Lene Dreyer,Merete Lund Hetland,René Cordtz,Kimme L. Hyrich,Anja Strangfeld,Angela Zink,Helena Canhão,M. Victoria Hernández,Florence Tubach,Jacques-Eric Gottenberg,Jacques Morel,Jakub Zavada,Florenzo Iannone,Johan Askling,Joachim Listing +20 more
TL;DR: While the subtype distribution differs between RA and the general population, there was no evidence of any modification of the distribution of lymphoma subtypes in patients with RA treated with TNFi compared with bionaïve patients.
The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta- analyses
TL;DR: Clinicians should remain vigilant for infection in patients with RA treated with GC therapy, as RCTs suggested no increased risk of infection, but marked heterogeneity, probable residual confounding, and publication bias limits the opportunity for a definitive conclusion.
Predictors of distress in female breast cancer survivors: a systematic review
Ania Syrowatka,Aude Motulsky,Aude Motulsky,Siyana Kurteva,James A. Hanley,William G Dixon,Ari N. Meguerditchian,Ari N. Meguerditchian,Robyn Tamblyn +8 more
TL;DR: This review established a set of evidence-based predictors that can be used to help identify women at higher risk of experiencing distress following completion of primary breast cancer treatment to help guide targeted intervention to prevent distress.
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
James Galloway,Kimme L. Hyrich,Louise K. Mercer,William G Dixon,Bo Fu,Andrew Ustianowski,Kath D. Watson,Mark Lunt,Deborah P M Symmons +8 more
TL;DR: In this article, the authors evaluated the risk of serious infections (SIs) in patients with RA treated with anti-TNF therapy with emphasis on the risk across different ages using data from the British Society for Rheumatology Biologics Register, a prospective observational study.
Exposure measurement error when assessing current glucocorticoid use using UK primary care electronic prescription data.
Rebecca M. Joseph,Tjeerd van Staa,Tjeerd van Staa,Mark Lunt,Michal Abrahamowicz,William G Dixon +5 more
TL;DR: To quantify misclassification in glucocorticoid (GC) exposure defined using UK primary care prescription data, data is used to establish a baseline for GC exposure and establish an apples-to- apples comparison between GC and non-GC exposure.